ACTIVITY OVERVIEW
The 2023 Symposium will focus on recent advances in the diagnosis, classification and management of patients with myelodysplastic syndromes (MDS). The program combines recent data, application of new tools and evidence on current practice with information that might be applied in the future.
AGENDA TOPICS
LEARNING OBJECTIVES
Participants will learn about novel information obtained over the last decade and will hear about potential applications in the field of MDS.
More specifically practitioners and researchers:
FACULTY
Professor of Medicine
Department of Medicine
Tel-Aviv Sourasky Medical Center
Tel-Aviv University Medical School
Tel-Aviv, Israel
Associate Professor, Department of Medicine
Odette Cancer Center
Toronto, Ontario, Canada
Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida, USA
Professor of Hematology
Fondazione IRCCS Policlinico San Matteo
University of Pavia
Pavia, Italy
Assistant Professor
University of Wisconsin School of Medicine and Public Health
Carbone Cancer Center
Madison, Wisconsin, USA
Humanitas Research Hospital, & Humanitas University
Rozzano Milan, Italy
McCredie Professor of Medicine
Vice Chair, Department of Leukemia
Chief, Section of MDS
The University of Texas MD Anderson Cancer Center
Houston, TX, USA
The University of Texas MD Anderson Cancer Center
Houston, TX, USA
Dana Farber Cancer Institute
Boston, MA, USA
Cleveland Clinic
Cleveland, OH, USA
Director
Medical Clinic and Policlinic 1
Hematology and Cellular Therapy
University Hospital Leipzig
Leipzig, Germany
Head, Clinical Hematology & Hematopoietic
Cell Transplantation Unit
Hospital Universitario y Politecnico La Fe
Valencia, Spain
Professor of Medicine and Cancer Biology
Vanderbilt University School of Medicine
Nashville, Tennessee, USA
Icahn School of Medicine at Mount Sinai
Director Translational Research Center for the Myelodysplastic Syndrome
Tisch Cancer Institute
New York City, New York, USA
AGENDA
Co-Chairs: Moshe Mittelman, MD (Tel-Aviv, Israel) & Rena Buckstein, MD (Toronto, Canada)
07.00 – 07.05 am | Welcome S. Nimer |
07.05 – 07.10 am | MDS challenges in 2023 M. Mittelman |
07.10 – 07.15 am | Program overview R. Buckstein |
07.15 – 07.30 am | Lecture: A classification of myelodysplastic syndromes that aids clinical decision-making M. Cazzola |
07.30 – 07.35 am | Q & A |
07.35 – 07.50 am | Lecture: Pre-MDS states: CH, CCUS, ICUS – How to manage in the clinic? M. Savona |
07.50 – 07.55 am | Q & A |
07.55 – 08.20 am | Debate I: ESA- Still the 1st line for LR-MDS? M. Della Porta & A. Giagounidis |
08.20 – 08.35 am | Lecture: Artificial intelligence in MDS practice A. Nazha |
08.35 – 08.40 am | Q & A |
08.40 – 09.00 am | Patient discussion I Expert panel: J. Churpek, G. Sanz, L. Silverman |
09.00 – 09.15 am | Patient discussion II Expert panel: J. Churpek, G. Sanz, L. Silverman |
09.15 – 09.30 am | Lecture: Can we do better than HMA in HR-MDS? G. Garcia-Manero |
09.30 – 09.35 am | Q & A |
09.35 – 09.55 am | Debate II: Should cytoreduction precede transplant? U. Platzbecker & C. Gibson |
09.55 – 10.00 am | Closing Remarks M. Mittelman or R. Buckstein |
*Activity and faculty subject to change
**Please note that CME Credits will only be available to those who attend live to continuing education credits. CME is typically for physicians only; the event offers credit for pharmacy and nurses.